Skip to main content

Show 30 results Show all

Self-injected subcutaneous DMPA: A new frontier in advancing contraceptive access and use for women

This brief details the strong body of evidence and experience with self-injection of DMPA-SC in low-resource settings, including how the practice can reduce access-related barriers, improve contraceptive continuation, and enhance women’s autonomy.

Institutional Author(s): PATH
Publication date: October, 2019

Resources: A list of references about subcutaneous DMPA

This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.

Institutional Author(s): PATH
Publication date: October, 2019

An overview of subcutaneous DMPA: A new type of injectable contraception that expands access and options

This brief offers quick facts on the benefits of DMPA-SC; the product’s potential for empowering women and adolescent girls; the product’s availability; and how subcutaneous DMPA is different from intramuscular DMPA (DMPA-IM).

Institutional Author(s): PATH
Publication date: October, 2019

Advocacy pack for subcutaneous DMPA: Tools for advocacy and communications to increase access to a new type of injectable contraception

Subcutaneous DMPA (DMPA-SC) is an innovative and easy-to-use injectable that is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates have an important role to play in making sure their country’s policies and funding support access to a broad method mix, including new options like DMPA-SC.

The Advocacy Pack for Subcutaneous DMPA is designed to accelerate your advocacy efforts. It consists of evidence-based materials, in English and French, for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Materials are customizable and unbranded so that you can tailor them to your country context.

Institutional Author(s): PATH
Publication date: October, 2019

Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

This press release announces the price reduction of Sayana Press from $1 to $0.85 per dose in qualifying countries.

Institutional Author(s): Pfizer, Inc.
Publication date: May, 2017

Brief Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

WHO Selected practice recommendations for contraceptive use

Along with WHO’s Medical eligibility criteria for contraceptive use, this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This document provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. Safety considerations include common barriers to safe, correct and consistent use of contraception and the benefits of preventing unintended or unwanted pregnancy.

Institutional Author(s): World Health Organization (WHO)
Publication date: June, 2016

Guide Web page

Medical Eligibility Criteria for Contraceptive Use

The MEC provides guidance to national family planning and reproductive health programmes in the preparation of guidelines for the delivery of contraceptive services. The guide provides information on the safety and use of intramuscular and subcutaneous DMPA.

Institutional Author(s): World Health Organization (WHO)
Publication date: August, 2015

Guide Web page

The Highs, Lows, and Squishy Middle of Contraceptive Product Introduction

As part of the Global Health Science and Practice (GHTechX) conference, CHAI, FHI 360, PATH, the Population Council, PSI, and WCG hosted an April 22, 2021 session to synthesize lessons learned across contraceptive introduction of implants, DMPA-SC self-injection, hormonal IUS and other methods. During the session, experts from Kenya, Madagascar, Uganda, and the United States outlined essential steps for the process of contraceptive product introduction, described common challenges, and shared tools and approaches based on experiences with the three methods. Session slides are available below. To watch the recording of this and many other sessions, register for free on the GHTechX website.

Institutional Author(s): Clinton Health Access Initiative (CHAI), FHI 360, PATH, Population Council, PSI
Publication date: April, 2021

Evidence at-a-glance: What we know about subcutaneous DMPA, a new type of injectable contraception

This brief outlines existing evidence on DMPA-SC with data grouped into top-line, evidence-based messages, with corresponding data from different countries. This handout can be printed and distributed directly to decision-makers. It contains several one-page spotlight handouts on specific sub-topics, which can be printed and paired with the two-page summary—for distribution to decision-makers—as needed.

Institutional Author(s): PATH
Publication date: October, 2019

Costs and cost-effectiveness of subcutaneous DMPA through different delivery channels: What new evidence tells us

This brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

Institutional Author(s): PATH
Publication date: October, 2019